Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: iStock
The World Health Organization (WHO) today released updated guidelines aimed at reducing the risk of cognitive decline and dementia, a condition that affects more than 57 million people worldwide.
Nearly 10 million people are diagnosed with dementia every year. While there is currently no cure, the WHO says up to 45 per cent of dementia risk can be prevented or delayed by addressing modifiable risk factors such as tobacco and alcohol use, physical inactivity, social isolation, air pollution, and noncommunicable diseases (NCDs), including high blood pressure and diabetes.
Beyond its impact on memory, thinking and daily functioning, dementia also affects a person's independence, dignity and safety.
"We know more today than ever before about what drives dementia risk, and these guidelines translate that knowledge into action," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
"Countries now have clear, evidence-based recommendations they can put into practice immediately to protect people's cognitive health," he added.
Also read: Healthy Lifestyle Changes Improve Memory, Thinking In Older Adults At Dementia Risk: The Lancet
The WHO last issued recommendations on dementia risk reduction in 2019. The global healthy body said that the updated guidelines incorporate the latest scientific evidence and innovations in dementia prevention. The revised recommendations also provide proven interventions that can lower dementia risk through early awareness and timely action.
Further, they present an opportunity to reduce the global burden of dementia by strengthening the integration of brain health with noncommunicable disease and mental health services.
Importantly, the updated guidelines recommend several healthy behaviors and lifestyle interventions to reduce the risk of cognitive decline and dementia, including:
The WHO also recommends effective management of cardiometabolic conditions such as hypertension, diabetes and high cholesterol as part of dementia risk-reduction strategies. Hearing aids may also be offered where appropriate, it said.
The WHO does not recommend the routine use of vitamin B and E supplements, omega-3 polyunsaturated fatty acids (PUFA), or multivitamins and minerals to prevent cognitive decline or dementia in people without a diagnosed deficiency.
According to the organization, current evidence does not demonstrate sufficient benefit to outweigh potential harmful effects.
Dementia is an umbrella term describing a significant decline in mental function that interferes with everyday life. It commonly affects memory, thinking and reasoning abilities and is caused by underlying conditions such as Alzheimer's disease or vascular dementia.
Read More: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For
Common Signs of Dementia
Dementia significantly affects an individual's ability to live independently, work and perform daily activities while placing a substantial burden on families and caregivers.
According to the WHO, dementia costs the global economy an estimated US$1.3 trillion every year, with about half of that amount attributed to unpaid care provided by family members and friends.
The WHO said understanding dementia risk factors and taking preventive action can improve health and quality of life, helping people live longer, healthier and more independent lives.
Credit: iStock
A simple blood test that measures androgen hormone levels could help diagnose endometriosis with more than 95 per cent accuracy, according to new research.
The University of Edinburgh-led findings offer hope for a faster, less invasive way to detect the condition, which affects an estimated 10 per cent of women of reproductive age worldwide—around 190 million people—and often takes years to diagnose.
The researchers found that women with endometriosis have a distinct androgen hormone profile in their blood, suggesting the condition could one day be identified through a simple blood test rather than invasive procedures.
Also read: NHS To Roll Out Two 'Gamechanger' Tests for Faster Endometriosis Diagnosis: Know How They Work
The research team analyzed blood samples from 159 women with confirmed endometriosis and 57 women without the condition. Their investigation focused on androgen hormones, including a lesser-studied group known as 11-oxygenated androgens, which are produced by the adrenal glands.
The researchers discovered that women with endometriosis consistently had higher levels of 11-ketotestosterone, one of the 11-oxygenated androgens.
Using this distinct hormone profile, the team was able to differentiate women with and without endometriosis, correctly identifying more than 95 per cent of those with the condition.
If validated in larger clinical studies, the test could reduce reliance on invasive diagnostic procedures such as laparoscopy and help women receive treatment much earlier.
The findings also provide new insights into the role of androgens in the development of endometriosis and may help guide future treatment strategies.
Endometriosis occurs when tissue similar to the lining of the uterus grows outside the womb. These cells respond to hormones, leading to inflammation, chronic pelvic pain and the formation of scar tissue.
While the disease is known to be influenced by the female hormones estrogen and progesterone, the role of androgens—often referred to as male hormones, though they are naturally present in women as well—has received comparatively little attention.
The researchers believe the newly identified androgen signature could improve understanding of how the disease develops and progresses.
Read More: 13.5 Million Children Remain Zero-Dose In 2025 Despite Global Vaccination Gains: UN Report
Diagnosing endometriosis remains a major challenge. Current methods include ultrasound, MRI scans and laparoscopy—a surgical procedure in which a camera is inserted through a small incision in the abdomen to confirm the presence of endometrial-like tissue.
Because symptoms often overlap with those of other conditions, many women wait years before receiving a diagnosis. Earlier diagnosis could help reduce prolonged pain, limit disease progression and allow patients to begin treatment sooner, said the researchers, while stressing the need for larger studies.
According to the World Health Organization (WHO), endometriosis is a chronic condition in which tissue similar to the lining of the uterus grows outside the uterus. It most commonly affects the ovaries, fallopian tubes and the tissue lining the pelvis.
The condition can begin with a person's first menstrual period and continue until menopause. Common symptoms include severe pelvic pain, painful periods, pain during intercourse, bowel or urinary symptoms during menstruation, and difficulty conceiving.
Credit: iStock
The recent rise in COVID-19 cases and deaths in Andhra Pradesh has renewed concerns over the virus, prompting neighbouring states such as Tamil Nadu and Odisha to step up surveillance. Andhra Pradesh has reported three COVID-related deaths along with several active cases.
However, health experts say the current situation does not indicate a major public health threat and have urged people to focus on prevention rather than panic.
Tamil Nadu's Health Department has also clarified that there is no evidence of a highly virulent COVID-19 variant circulating in the state. Officials noted that current COVID-19 infections remain lower than in previous years.
Also read: Omicron Sub-Lineages Likely Behind COVID Surge In India: Why Deaths Are Occurring
"The SARS-CoV-2 virus never truly disappears; it continues to resurface through new mutations. Viral strains naturally mutate as part of their evolution, making viral illnesses highly dynamic," Dr Abha Mashur, Pulmonologist at Lilavati Hospital and Research Centre, Mumbai, told HealthandMe.
She said the key concern is not the emergence of new variants, but the severity of disease they cause.
"At present, we are predominantly seeing upper respiratory involvement and milder cases of viral illness," said Dr Mashur, adding that Lilavati Hospital has admitted only one or two COVID-19 patients recently, all of whom required monitoring but experienced only mild illness.
While most infections are mild, experts caution that certain groups remain vulnerable to severe disease. These include:
Read More: 13.5 Million Children Remain Zero-Dose In 2025 Despite Global Vaccination Gains: UN Report
According to Dr Mashur, the current wave is being driven by Omicron subvariants — the JN.1 variant and the BA.3.2 variant — that remain highly transmissible but are not causing severe illness in most people.
JN.1: The expert explained that the JN.1 variant is highly transmissible and possesses enhanced immune-evasion capabilities, allowing it to partially bypass immunity from previous infection or vaccination. However, she said it continues to cause predominantly mild illness compared to earlier variants.
BA.3.2: The BA.3.2 variant has accumulated a large number of mutations, raising concerns about immune escape. Despite this, available evidence suggests it has not led to more severe disease and is not currently considered a cause for alarm.
The experts stressed that the current rise in cases should encourage vigilance rather than fear. Vaccination, masking in high-risk settings, and early medical consultation remain the most effective tools to reduce transmission and protect vulnerable populations.
"The current situation should not create panic, but should prompt people to seek medical attention early. Those who develop symptoms of a viral infection should avoid public spaces and consult a doctor promptly so that transmission can be curtailed at the earliest," Dr Mashur said.
Dr Neha Rastogi, Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurugram, urged people to continue following basic preventive measures.
"To reduce the risk of infection, people should stay up to date with COVID-19 vaccinations, wear masks in crowded indoor settings, maintain hand hygiene, ensure good ventilation, and avoid close contact when unwell. Anyone experiencing symptoms such as fever, cough, or breathlessness should get tested and seek timely medical advice."
© 2024 Bennett, Coleman & Company Limited